22nd Jun 2005 11:30
FOR IMMEDIATE RELEASE22 June 2005Shire Pharmaceuticals Group plc AGM - 2005Results of the Annual General MeetingShire Pharmaceuticals Group plc held its Annual General Meeting today. Allresolutions were put to the meeting and approved on a show of hands. The proxyvotes received for the meeting are set out below: For Against Abstention 1. To receive and consider 390,982,100 652,340 3,146,277 the directors' report and accounts for the year ended 31 December 2004 2. To re-elect Mr Matthew 389,563,578 3,279,709 1,937,430 William Emmens as a director 3. To re-elect Mr Ronald 387,779,176 3,082,640 3,918,901 Maurice Nordmann as a director 4. To re-elect Dr Barry 386,034,142 3,946,865 4,799,710 John Price as a director 5. To re-appoint Deloitte 387,710,401 4,642,337 2,427,979 & Touch LLP as Auditors 6. To authorise the Audit 392,716,407 1,103,374 960,936 Committee to determine the remuneration of the Auditors 7. To approve the 379,661,987 6,796,998 8,321,732 Directors' Remuneration Report 8. To authorise the 390,798,549 2,930,801 1,051,367 allotment of shares 9. To authorise the 390,522,104 3,182,677 1,075,936 disapplication of pre-emption rights 10. To authorise market 393,533,510 172,481 1,074,726 purchases 11. To authorise donations 384,375,349 7,229,220 3,176,148 to EU political organisations and EU political expenditure For further information please contact:Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing projects and marketing products in theareas of central nervous system (CNS), gastrointestinal (GI), and renaldiseases. Shire has operations in the world's key pharmaceutical markets (US,Canada, UK, France, Italy, Spain and Germany) as well as a specialist drugdelivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com."SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF1995Statements included herein that are not historical facts are forward-lookingstatements. Such forward-looking statements involve a number of risks anduncertainties and are subject to change at any time. In the event such risks oruncertainties materialize, Shire's results could be materially affected. Therisks and uncertainties include, but are not limited to, risks associated withthe inherent uncertainty of pharmaceutical research, product development,manufacturing and commercialization, the impact of competitive products,including, but not limited to, the impact of those on Shire's ADHD franchise,patents, including but not limited to, legal challenges relating to Shire'sADHD franchise, government regulation and approval, including but not limitedto Health Canada's suspension of ADDERALL XR⨠sales in Canada and the expectedproduct approval dates of MTS (METHYPATCH) (ADHD), SPD503 (ADHD), SPD465(ADHD), SPD476 (ulcerative colitis), SPD480 (ulcerative colitis) and NRP104(ADHD), including its scheduling classification by the Drug Enforcement Agencyin the United States, Shire's ability to consummate and benefit from itsproposed acquisition of TKT, Shire's ability to secure new products forcommercialization and/or development and other risks and uncertainties detailedfrom time to time in Shire's filings with the Securities and ExchangeCommission, including its Annual Report on Form 10-K for the year to December31, 2004.2Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire